Despite incremental progress in the treatment of acute coronary syndromes (ACS), major uncertainties remain about the translation of evidence from trials into improved clinical practice. Key publications in 2010 have addressed this issue and questioned whether specific ACS therapies should be targeted according to clinical and genetic characteristics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bassand, J. P. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28, 1598–1660 (2007).
Anderson, J. L. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons, endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. 14, e1–e157 (2007).
Fox, K. A. A. et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data. J. Am. Coll. Cardiol. 55, 2435–2445 (2010).
Mega, J. L. et al. Reduced-function CYP1C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821–1830 (2010).
Mega, J. L. et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. Lancet 376, 1312–1319 (2010).
Wallentin, L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376, 1320–1328 (2010).
MINAP Steering Committee. MINAP 2010 Report: Myocardial Ischaemia National Audit Project [online], (2010).
National Institute for Health and Clinical Excellence. Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction. Clinical guideline 94 [online], (2010).
FDA drug safety communication. Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug [online], (2010).
Paré, G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363, 1704–1714 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
K. A. A. Fox is on the speaker's bureau for Sanofi-Aventis and receives grant/research support from Bayer, Eli Lilly, Johnson & Johnson and Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Fox, K. Progress from trials to practice. Nat Rev Cardiol 8, 68–70 (2011). https://doi.org/10.1038/nrcardio.2010.207
Published:
Issue date:
DOI: https://doi.org/10.1038/nrcardio.2010.207
